Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)
<b>Background</b>: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders. However, it has poor oral bioavailability. We investigated the effect of a novel lipid formulation on its absorption in humans and on its tiss...
Saved in:
Main Authors: | Edward Chesney, Ndabezinhle Mazibuko, Dominic Oliver, Amedeo Minichino, Ayşe Doğa Lamper, Lucy Chester, Thomas J. Reilly, Millie Lloyd, Matilda Kråkström, Alex M. Dickens, Matej Orešič, Eric Lynch, Gregory Stoloff, Mitul A. Mehta, Philip McGuire |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/16/12/1537 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chemical analysis and concentrations of cannabidiol substances used for refractory epilepsy in Chilean patients. An underestimated worldwide risk
by: Loreto Ríos‐Pohl, et al.
Published: (2024-12-01) -
Patterns of cannabidiol use among marijuana users in the United States
by: Ji-Yeun Park
Published: (2025-02-01) -
Intraperitoneal delivery of cannabidiol (CBD) and Δ9-tetrahydocannabinol (THC) promotes papillomavirus infections in athymic nude mice
by: Sarah A. Brendle, et al.
Published: (2025-06-01) -
CBD for pets: navigating quality assurance, safety standards, and marketing strategies
by: Hannah Rideout, et al.
Published: (2025-01-01) -
Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs
by: Phannicha Kosukwatthana, et al.
Published: (2024-12-01)